Oxford, UK, May 29, 2008
PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector. “PharmaVentures has always strived to make deal-making easier”, says Chief Executive, Fintan Walton,. “For the last 12 years, our PharmaDeals database has been a trusted resource for leading pharmaceutical and biotechnology companies, as well as law firms, financial institutions and universities from around the world. In launching the new PharmaDeals v2 database, we have not only leveraged our unrivalled expert knowledge, but have also made sure we teamed up with world-class database experts, top Web 2.0 technologists and designers to bring to fruition this innovating database. It’s an exciting time for us.”
Managing the development is Steven Renwick, Associate Publisher, a deal-making professional and expert on licensing. Dr Renwick says, “The PharmaDeals database content has always been well-respected, but we wanted to give our customers much more utility, and improve the way data is accessed and presented. This meant that we actually had to break the PharmaDeals database down into its constituent parts and rebuild it from scratch – an exhaustive but rewarding experience. We carefully mapped out new database structures and content, and topped that with a specially crafted search facility. And then, of course, we are putting on all the bells and whistles of any self-respecting Web 2.0 site.”
“We wanted to bring the new benefits of our database to our customers as quickly as possible”, continues Dr Renwick, “and so the best way was to launch a beta version of PharmaDeals v2 and to solicit feedback from our loyal user-base. For us, this launch is also another beginning; we have plans to roll out further advanced features in the coming weeks and months to serve our highly discerning client base.”
The new PharmaDeals v2 is a business and research tool with many applications, including the benchmarking of deals, analyzing competitor activity, tracking development of particular deals, and investigating the landscape of emerging deals and alliances. The database delivers a fresh user interface and a sophisticated search function to navigate 28,000+ deals. New features include mapping of pharmaceutical products according to the recognised, international classification of diseases, as well as an enhanced classification of product types and a rigorous classification of license territories. The development also introduces new personalisation features, including a watch list and associated email alerting service. Customers will now also benefit from flexible delivery options, including IP domain-authenticated access and xml feeds.
All subscribers to the PharmaDeals v2 will receive access to PharmaDeals Review, the online publication and associated article archive that offers users an intelligence layer that augment comprehensive data records. As well as timely, insightful and concise articles on deals news, PharmaDeals Reviews offers contributed feature articles from industry-leading writers. Subscribers also benefit from context-sensitive access to recent and archived videos released by PharmaTelevision, PharmaVentures’ online TV channel, featuring compelling interviews with industry-leading figures.
Fintan Walton concludes, “The news about our new database is spreading fast, and early reaction is highly positive from both our existing clients, and others looking for a premier deals database and intelligence. With PharmaDeals v2, we truly have set a new standard and are extremely proud of this achievement.”
PharmaDeals® is a registered trademark of PharmaVentures Ltd.
PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored transaction advisory services to the Life Science industry. PharmaVentures is based in Oxford, UK, and employs over 35 people. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporations.
- ends -